Claims

1. Use of a capsule fill formulation comprising a selective progesterone receptor modulator (SPRM) and one or more excipients in the manufacture of a medicament for treating a progesterone-dependent condition selected from the group consisting of endometriosis and pain associated therewith, adenomyosis, endometriomas of the ovary, dysmenorrhea, uterine fibroids, endometrial hyperproliferation, ovarian cancer, and cervical cancer, wherein the medicament is contained in a mucoadhesive capsule comprising pullulan, and wherein the medicament is for administration to the vaginal mucosa of a female in need thereof.

2. The use according to claim 1, wherein the capsule comprises about 85 to 90 wt % pullulan.

3. The use according to claim 1, wherein the SPRM is CDB-4124. 20.

4. The use according to claim 1, wherein the medicament is for daily administration at a dosage of about 1 mg to 50 mg.

Claims

1. Use of a capsule fill formulation comprising a selective progesterone receptor modulator (SPRM) and one or more excipients in the manufacture of a medicament for treating a progesterone-dependent condition selected from the group consisting of endometriosis and pain associated therewith, adenomyosis, endometriomas of the ovary, dysmenorrhea, uterine fibroids, endometrial hyperproliferation, ovarian cancer, and cervical cancer, wherein the medicament is contained in a mucoadhesive capsule comprising pullulan, and wherein the medicament is for administration to the vaginal mucosa of a female in need thereof.

2. The use according to claim 1, wherein the capsule comprises about 85 to 90 wt % pullulan.

3. The use according to claim 1, wherein the SPRM is CDB-4124.

4. The use according to claim 1, wherein the medicament is for daily administration at a dosage of about 1 mg to 50 mg.